eLife (Jul 2020)

Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice

  • Ying Ann Chiao,
  • Huiliang Zhang,
  • Mariya Sweetwyne,
  • Jeremy Whitson,
  • Ying Sonia Ting,
  • Nathan Basisty,
  • Lindsay K Pino,
  • Ellen Quarles,
  • Ngoc-Han Nguyen,
  • Matthew D Campbell,
  • Tong Zhang,
  • Matthew J Gaffrey,
  • Gennifer Merrihew,
  • Lu Wang,
  • Yongping Yue,
  • Dongsheng Duan,
  • Henk L Granzier,
  • Hazel H Szeto,
  • Wei-Jun Qian,
  • David Marcinek,
  • Michael J MacCoss,
  • Peter Rabinovitch

DOI
https://doi.org/10.7554/eLife.55513
Journal volume & issue
Vol. 9

Abstract

Read online

Diastolic dysfunction is a prominent feature of cardiac aging in both mice and humans. We show here that 8-week treatment of old mice with the mitochondrial targeted peptide SS-31 (elamipretide) can substantially reverse this deficit. SS-31 normalized the increase in proton leak and reduced mitochondrial ROS in cardiomyocytes from old mice, accompanied by reduced protein oxidation and a shift towards a more reduced protein thiol redox state in old hearts. Improved diastolic function was concordant with increased phosphorylation of cMyBP-C Ser282 but was independent of titin isoform shift. Late-life viral expression of mitochondrial-targeted catalase (mCAT) produced similar functional benefits in old mice and SS-31 did not improve cardiac function of old mCAT mice, implicating normalizing mitochondrial oxidative stress as an overlapping mechanism. These results demonstrate that pre-existing cardiac aging phenotypes can be reversed by targeting mitochondrial dysfunction and implicate mitochondrial energetics and redox signaling as therapeutic targets for cardiac aging.

Keywords